...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension
【24h】

Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension

机译：肺动脉高压患者的血清CD163和TWEAK水平

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Inflammation may play a pivotal role in the pathogenesis of pulmonary arterial hypertension (PAH). We evaluated the concentrations of serum sTWEAK, its scavenger receptor sCD163 and sTWEAK/sCD163 ratio in patients with PAH. Design: The study enrolled 26 stable patients with PAH confirmed by right heart catheterization and 24 healthy volunteers matched for age, sex and body weight. All patients underwent transthoracic echocardiography, cardiopulmonary exercise test, 6-min walk test, measurement of lung diffusing capacity for the carbon monoxide (DLCO) and venous blood tests. Concentrations of sTWEAK and sCD163 were determined using ELISA kits. Results: The PAH patients were characterized by significantly higher median serum sCD163 levels (1072 vs 890ng/ml, p=0.04) together with lower serum sTWEAK concentrations (200 vs 278.1pg/ml, p=0.003) comparing to control subjects. sTWEAK/sCD163 ratio was therefore significantly lower in PAH group (0.18 vs 0.33, p=0.0005). No correlation was found between sTWEAK and sCD163 concentrations in both groups. We observed statistically significant inverse correlation between peak VO2 consumption and sCD163 concentrations (r=-0.52, p0.05) and positive with sTWEAK/sCD163 ratio (r=0.45, p0.05) in PAH group. Moreover, sTWEAK/sCD163 ratio positively correlated with % of predicted values of DLCO (r=0.42, p0.05). Conclusions: Patients with PAH present altered serum sTWEAK and sCD163 levels. The sTWEAK/sCD163 ratio appears to be a better indicator of the severity of PAH as compared to sTWEAK or sCD163 alone. The exact role of sCD163 or interaction between CD163 and sTWEAK in the initiation or progression of PAH as well as their potential prognostic significance remains to be established.
机译：背景：炎症可能在肺动脉高压（PAH）的发病机理中起关键作用。我们评估了PAH患者血清sTWEAK，其清道夫受体sCD163和sTWEAK / sCD163的浓度。设计：该研究招募了通过右心导管检查确诊的26例稳定的PAH患者，以及年龄，性别和体重相匹配的24名健康志愿者。所有患者均接受经胸超声心动图检查，心肺运动试验，6分钟步行试验，一氧化碳（DLCO）肺扩散能力测定和静脉血液检查。使用ELISA试剂盒确定sTWEAK和sCD163的浓度。结果：与对照组相比，PAH患者的特征是血清sCD163的中位数水平明显升高（1072 vs 890ng / ml，p = 0.04），血清sTWEAK浓度较低（200 vs 278.1pg / ml，p = 0.003）。因此，PAH组的sTWEAK / sCD163比值显着降低（0.18比0.33，p = 0.0005）。两组中sTWEAK和sCD163浓度之间均未发现相关性。我们观察到PAH组的峰值VO2消耗量与sCD163浓度（r = -0.52，p <0.05）和sTWEAK / sCD163比值呈正相关（r = 0.45，p <0.05）之间具有统计学意义的负相关。此外，sTWEAK / sCD163比值与DLCO预测值的百分比呈正相关（r = 0.42，p <0.05）。结论：PAH患者的血清sTWEAK和sCD163水平改变。与单独的sTWEAK或sCD163相比，sTWEAK / sCD163比率似乎是PAH严重程度的更好指标。 sCD163或CD163和sTWEAK之间相互作用在PAH起始或进展中的确切作用及其潜在的预后意义尚待确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号